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To date, 18 living recommendations for the clinical care of pregnant and postpar-
tum women with COVID-19 have been issued by the National COVID-19 Clinical 
Evidence Taskforce. This includes recommendations on mode of birth, delayed 
umbilical cord clamping, skin-to-skin contact, breastfeeding, rooming-in, antena-
tal corticosteroids, angiotensin-converting enzyme inhibitors, disease-modifying 
treatments (including dexamethasone, remdesivir and hydroxychloroquine), ve-
nous thromboembolism prophylaxis and advanced respiratory support interven-
tions (prone positioning and extracorporeal membrane oxygenation). Through 
continuous evidence surveillance, these living recommendations are updated in 
near real-time to ensure clinicians in Australia have reliable, evidence-based guide-
lines for clinical decision-making. Please visit https://covid 19evi dence.net.au/ for 
the latest recommendation updates.
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INTRODUCTION
The first cases of novel coronavirus SARS-CoV-2 infection were 
reported in December 2019 in Wuhan, China.1 Novel coronavi-
rus disease 2019 (COVID-19) was declared a global pandemic by 
the World Health Organization on 11 March 2020, and as of 17 
September 2020, there have been over 3068 million confirmed 
cases and more than 954 000 deaths globally.2 In Australia, there 
have been 26  942 confirmed cases and 854 deaths.3 COVID-19 
commonly presents with fever and respiratory symptoms in-
cluding cough and shortness of breath; other symptoms (such 
as myalgia, sore throat, fatigue, diarrhoea and anosmia) are less 
common.4 An estimated 15% of infected individuals will develop 
severe disease (requiring oxygen support) and 5% will progress 
to critical disease.4 Critical COVID-19 disease is characterised by 
respiratory failure, acute respiratory distress syndrome (ARDS), 
thromboembolism, sepsis, shock or multiorgan failure. After re-
covery from acute illness, some individuals may experience lon-
ger-term sequelae, particularly respiratory complications.5
Experience from previous pandemics (H1N1) and coronavi-
rus outbreaks (SARS and MERS) raised concerns that pregnant 
women may be particularly vulnerable to more severe COVID-19 
disease.6,7 While current data are limited, pregnant and recently 
pregnant women with COVID-19 are less likely to experience fever 
and myalgia, compared with non-pregnant women of reproduc-
tive age.8 However, they have higher rates of intensive care unit 
admission or invasive ventilation, and their babies are more 
likely to be born preterm or require neonatal unit admission.8 
Epidemiological data from the Latin American region suggest 
maternal deaths may be increasing due to COVID-19.9 Vertical 
transmission appears possible although probably rare.10,11
In response to the COVID-19 pandemic, state, national and 
international organisations rapidly developed clinical guidelines 
on how best to care for pregnant and postpartum women with 
COVID-19.12 Ideally, clinical guidelines are developed using sys-
tematic reviews of available evidence to address pre-specified 
questions, with expert panels formulating recommendations 
based on this evidence. However, many such recommendations 
become outdated as new evidence emerges.13,14 This is a par-
ticular challenge in the COVID-19 context, where the volume of 
COVID-19-related literature is increasing dramatically.15 Living 
guideline methodologies were developed to meet such chal-
lenges.16 In living guidelines, digital technologies and continuous 
evidence surveillance are used to continually update systematic 
reviews and recommendations, so as to reflect the latest available 
evidence.17 This approach has been used successfully in stroke, 
diabetes, maternal health and other topics.18–20
The National COVID-19 Clinical Evidence Taskforce was es-
tablished in March 2020 to produce living recommendations on 
the clinical care of people with COVID-19 in Australia.21 As of 17 
September 2020, the Taskforce has published 72 recommenda-
tions on disease severity, disease-modifying treatments, chemo-
prophylaxis, respiratory support, venous thromboembolism (VTE) 
prophylaxis, and use of therapies for pre-existing conditions, as 
well as specific recommendations on the care of women, neo-
nates, children, adolescents, older people and people in pallia-
tive care with COVID-19. The aim of this article is to describe the 
Taskforce recommendations for the care of pregnant and post-
partum women with COVID-19.
METHODS
The living guidelines are being developed according to Australian 
National Health and Medical Research Council (NHMRC) stand-
ards, including the use of GRADE (Grading of Recommendations 
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Assessment, Development and Evaluation) methodology.22 The 
Taskforce brings together over 220 clinical experts from across 
Australia to assess the latest evidence and keep recommenda-
tions up-to-date on a weekly basis. All outputs are overseen by 
a Steering Committee composed of representatives from 31 
peak health professional bodies, including the Australian College 
of Midwives (ACM) and the Royal Australian and New Zealand 
College of Obstetricians and Gynaecologists (RANZCOG).23 The 
Taskforce’s remit is to focus on the clinical care of people with 
COVID-19, with other national agencies responsible for produc-
ing guidance on infection prevention, control and diagnosis. The 
Taskforce also produces clinical flowcharts to facilitate translation 
of living recommendations into clinical practice.24 As these living 
recommendations are regularly updated with new evidence, we 
encourage clinicians to visit https://covid 19evi dence.net.au/ and 
freely subscribe to the weekly updates.
The Guidelines Leadership Group (GLG) oversees seven expert 
panels developing recommendations for primary, hospital and crit-
ical care settings. An evidence review team composed of experi-
enced systematic reviewers and guideline methodologists identifies, 
appraises and synthesises evidence to inform the development of 
these recommendations. The Taskforce uses the MAGIC (Making 
GRADE the Irresistible Choice) digital platform for formulating and 
publishing recommendations.25 The multi-disciplinary Pregnancy 
and Perinatal Care panel (one of seven panels) is composed to ensure 
diverse representation of setting, culture, geography and gender. It 
includes 13 experts from Aboriginal and Torres Strait Islander health, 
general practice, infectious diseases, midwifery, neonatology, obstet-
rics and gynaecology, obstetric anaesthesia, perinatal epidemiology, 
public health, and rural and remote medicine. Recommendations 
formulated by any panel are reviewed and approved by the GLG and 
the Steering Committee, prior to their publication.
Identification and formulation of 
clinical questions
We conducted a systematic mapping of available guidelines on the 
antenatal, intrapartum and postpartum care of women during the 
COVID-19 pandemic, identifying 81 guidelines from 48 organisa-
tions in Australia and internationally.12 This mapping informed a 
prioritisation by panel members, who ranked a shortlist of clinical 
questions on the basis of: (1) interventions that are likely to impact 
on patient outcomes; (2) proportion of clinical population impacted; 
(3) extent of variation in current practice; and (4) likelihood of new 
evidence emerging. The panel also reviewed existing Taskforce rec-
ommendations on the clinical care of adults with COVID-19 to iden-
tify those clinical questions where adaptation was needed.
Literature searching, data 
collection and synthesis
An information specialist oversees the evidence surveillance pro-
cess, which combines daily searches of COVID-19-related articles 
and preprints across broad topic areas (such as pregnancy and 
newborn care) with targeted searches for specific clinical questions 
as they are proposed by the expert panels.26 The evidence review 
team uses Covidence,27 a collaborative online software for manag-
ing and streamlining systematic reviews, for screening literature. 
Titles and abstracts are initially screened by two reviewers inde-
pendently, with full texts of potentially eligible studies retrieved 
and also reviewed in duplicate. Disagreements are resolved 
through discussion or consultation with a third member of the evi-
dence review team. Eligible articles are primary research (typically 
trials) or systematic reviews relating to the clinical questions of 
interest. Systematic reviews (particularly living systematic reviews 
that are kept up-to-date) of reasonable quality are the preferred 
evidence source. If required, a limited update may be used to in-
tegrate findings from more recent primary studies into an exist-
ing systematic review. Where no such systematic review exists, the 
evidence review team initiates a new systematic review. For some 
clinical questions where direct trial evidence is unlikely to be avail-
able for pregnant and postpartum women, lower quality evidence 
such as observational studies or studies from related topics (eg, 
studies of women with ARDS due to other causes) are considered.
Data on study characteristics and priority outcomes are ex-
tracted in duplicate using standardised data collection forms, with 
disagreements resolved through discussion or consulting a third re-
viewer.27 Included studies are assessed using an appropriate quality 
assessment tool, such as AMSTAR 2 for systematic reviews and the 
Cochrane Risk of Bias 2.0 assessment tool for randomised trials.28–30
Developing and updating recommendations
Since 14 May 2020, the panel convened on a weekly basis to review 
the evidence, develop and update recommendations. Where nec-
essary, assistance is sought from additional expert advisory groups 
(eg, haematology, critical care). The panel reviews evidence pro-
files on the benefits, harms and certainty of the evidence for prior-
ity questions, as well as considering the resource requirements, 
cost-effectiveness, feasibility, acceptability and equity of each in-
tervention. This is done systematically using GRADE evidence to 
decision frameworks.22 Recommendations are formulated in line 
with established Australian maternity care principles, including 
the need for evidence-based, person-centred care that is respon-
sive to women’s needs and preferences.31 Recommendations are 
also reviewed by a separate Consumer Panel, co-convened by the 
Consumers Health Forum of Australia and the Taskforce. Ongoing 
literature surveillance is maintained for published recommenda-
tions. If relevant new studies become available, evidence profiles 
are updated and the recommendations may be revised.
RESULTS
The following recommendations are current as of 17 September 
2020, with any subsequent updates freely available at https://
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covid 19evi dence.net.au/. Classifications of disease severity used 
by the Taskforce are described in Table 1.
Pregnancy and perinatal care of women 
with COVID-19
Seven recommendations on mode of birth, delayed umbilical cord 
clamping, skin-to-skin contact, breastfeeding, rooming-in, ante-
natal corticosteroids and angiotensin-converting enzyme (ACE)-
inhibitors support continuing with the provision of usual care, 
although the need for masks and hand hygiene when mothers 
are caring and feeding their babies, is emphasised (Table 2).
While systematic reviews on the risks of vertical transmission 
by mode of birth, rooming-in status and different infant feed-
ing approaches have been published, only very low certainty 
evidence (predominantly case reports and case series) is cur-
rently available.32,33 Additional evidence is available from a US 
multi-centre cohort study of 106 neonates born to mothers who 
were positive for COVID-19.34 In this study, mode of birth, skin-
to-skin contact and breastfeeding were managed as per usual 
care, although maternal use of surgical masks, hand hygiene 
and breast cleansing were encouraged. Newborns roomed-in 
with mothers, except for 17 newborns who were separated at 
parental request or due to medical complications. Newborns 
were tested by nasopharyngeal polymerase chain reaction at 
12–24 h (n = 106), 5–7 days (n = 79) and 14 days (n = 72) of life, 
with all newborns testing negative at all timepoints. While the 
possibility of vertical transmission cannot be excluded based on 
this evidence, this must be weighed against the known, substan-
tial benefits of these interventions.35–42
No direct evidence was identified on delayed cord clamping in 
women with COVID-19, or on antenatal corticosteroids or use of 
ACE inhibitors for postpartum women with hypertension requir-
ing drug treatment. Hence, these recommendations are aligned 
with current Australian pregnancy and perinatal care guidance on 
use of these interventions.43–45
Use of disease-modifying treatments in women 
with COVID-19
Corticosteroids
Evidence on corticosteroids compared with standard care for 
COVID-19 in adults comes from eight randomised trials (over 5700 
patients), including the multi-centre RECOVERY trial that evaluated 
dexamethasone against usual care in 2104 patients.46,47 Pregnant 
women were specifically excluded from all trials, except for 
RECOVERY (six pregnant women enrolled) and REMAP-CAP (the 
number of pregnant women enrolled has not been reported).47,48 
Corticosteroids reduce mortality for adult patients with severe 
or critical COVID-19 (relative risk (RR) 0.86 95% Ci 0.77–0.97), 
and probably also reduce the need for mechanical ventilation or 
death, and time to discharge from hospital. However, in patients 
who do not require oxygen, corticosteroids may increase mortal-
ity (RR 1.27 95% CI 1.00–1.61). Considering these benefits and the 
likely acceptability of the intervention, using dexamethasone 6 mg 
TABLE 1 Classification of COVID-19 disease severity†
Mild illness Adults not presenting any clinical features suggestive of moderate or severe disease or a complicated course of illness.
Characteristics:
• no symptoms
• or mild upper respiratory tract symptoms
• or cough, new myalgia or asthenia without new shortness of breath or a reduction in oxygen saturation
Moderate illness Stable adult patient presenting with respiratory and/or systemic symptoms or signs. Able to maintain oxygen saturation 
above 92% (or above 90% for patients with chronic lung disease) with up to 4 L/min oxygen via nasal prongs.
Characteristics:
• prostration, severe asthenia, fever> 38°C or persistent cough
• clinical or radiological signs of lung involvement
• no clinical or laboratory indicators of clinical severity or respiratory impairment
Severe illness Adult patients meeting any of the following criteria:
• respiratory rate ≥ 30 breaths/min
• oxygen saturation ≤ 92% at a rest state
• arterial partial pressure of oxygen (PaO2)/ inspired oxygen fraction (FiO2) ≤300
Critical illness Adult patient meeting any of the following criteria:
Respiratory failure
1. Occurrence of severe respiratory failure (PaO2/FiO2 < 200), respiratory distress or acute respiratory distress 
syndrome (ARDS). This includes patients deteriorating despite advanced forms of respiratory support (noninvasive 
ventilation, high-flow nasal oxygen) OR patients requiring mechanical ventilation.
OR other signs of significant deterioration
• hypotension or shock
• impairment of consciousness
• other organ failure
†Recommendations were current at the time of writing. Please visit The National COVID-19 Clinical Evidence Taskforce (https://covid 19evi dence.
net.au/) for the latest updates to the recommendations.
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daily (IV or oral) for up to ten days is recommended in pregnant 
or breastfeeding women with COVID-19 who are receiving oxygen 
(Table 3). While the RECOVERY Trial specified that enrolled preg-
nant women receive oral prednisolone or intravenous hydrocorti-
sone,49 dexamethasone is preferred as it is used for other clinical 
indications in pregnancy.50 Corticosteroids should not be used in 
women with COVID-19 who do not require oxygen, due to the lack 
of benefit and possible harms in this subgroup.
Remdesivir
Four trials have compared remdesivir with standard care in hospi-
talised, non-pregnant adults with COVID-19.51–54 As pregnant and 
breastfeeding women were excluded from these trials, there is no 
direct evidence on the impact of remdesivir for COVID-19 in these 
women, as well as a lack of safety data on its use in pregnancy.55 
In non-pregnant adults, remdesivir may decrease time to recovery 
TABLE 2 Pregnancy and perinatal care recommendations for women with COVID-19†
Intervention Recommendation and remarks
Mode of birth For pregnant women with COVID-19, mode of birth should remain as per usual care (conditional recommendation, very low 
certainty evidence)
• There is currently no evidence to indicate that caesarean section for women with COVID-19 reduces the risk of verti-
cal transmission to the newborn. Mode of birth should continue as per usual care. Respiratory deterioration due to 




Delayed umbilical cord clamping is supported as part of standard care, independent of the presence of COVID-1 
(consensus recommendation)




Early skin-to-skin contact after birth and during the postnatal period is supported, irrespective of the presence of COVID-
19. However, parents with COVID-19 should use infection prevention and control measures (mask and hand hygiene) 
(consensus recommendation)
• Early skin-to-skin contact refers to placing the naked baby prone on the parent's bare chest immediately after birth.
• Skin-to-skin contact should be encouraged and continue as per usual practice in other postnatal and neonatal set-
tings, such as neonatal intensive care unit and postnatal wards, providing infection prevention and control measures 
are maintained.
Breastfeeding Breastfeeding is supported irrespective of the presence of COVID-19. However, women with COVID-19 who are 
breastfeeding should use infection prevention and control measures (mask and hand hygiene) while infectious 
(conditional recommendation, very low certainty evidence)
• There is currently no evidence to indicate that breastfeeding increases the risk of vertical transmission to the newborn. 
As there are substantial known benefits for breastfeeding, women should be supported to initiate or continue breast-
feeding. If the baby is being fed with expressed breastmilk or formula, these same infection prevention and control 
measures should be used.
Rooming-in For women with COVID-19 who have given birth, support rooming-in of mother and newborn in the birth suite and on the 
postnatal ward when both mother and baby are well. However, women with COVID-19 should use infection prevention 
and control measures (mask and hand hygiene) (conditional recommendation, very low certainty evidence)
• There is currently no evidence to indicate that a woman with a known COVID-19 infection should be separated from 
her newborn to prevent transmission. As there are substantial known benefits for keeping mother and newborn 
together postpartum, women should be supported to be with their newborn as per usual care.
• Women with COVID-19 should be encouraged and supported in using good hand hygiene before and after handling 
their baby, and using a mask while in close contact with their baby. To the extent possible, these women should prac-
tice physical distancing when not feeding or caring for the baby.
Antenatal 
corticosteroids
The use of antenatal corticosteroids for women at risk of preterm birth is supported as part of standard care, 
independent of the presence of COVID-19 (consensus recommendation)
• There are clear benefits to using antenatal corticosteroids for women at risk of preterm birth at less than 34 weeks 
gestation. There is currently no evidence to suggest that antenatal corticosteroids cause additional maternal or fetal 
harm in the setting of COVID-19 when used for this indication. They should therefore be given where indicated.
• The Taskforce has separate recommendations regarding the use of dexamethasone as a disease-modifying treatment 
in pregnant or breastfeeding women for COVID-19. Women with COVID-19 who are on oxygen and receiving dexa-







In postpartum women with COVID-19 who have hypertension requiring treatment with ACE inhibitors, there is 
currently no evidence to deviate from usual care. These medications should be initiated or continued unless otherwise 
contraindicated (consensus recommendation)
• ACE inhibitors are contraindicated in the antenatal period due to risk of fetal and neonatal harm.
†Recommendations were current at the time of writing. Please visit The National COVID-19 Clinical Evidence Taskforce (https://covid 19evi dence.
net.au/) for the latest updates to the recommendations. ACE, angiotensin-converting enzyme
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by a few days (hazards ratio (HR) 1.24, 95% CI 1.08–1.42) and time 
to improvement only slightly (HR 1.17, 95% CI 1.00–1.38). Its effect 
on mortality is uncertain, and it is currently unclear which regimen 
(five days or ten days) provides the most benefit. However, the 
panel noted that severity of disease is an important factor – for 
pregnant women with severe or critical COVID-19, the harm-to-
benefit ratio may differ compared to pregnant women with mild 
or moderate disease. The Taskforce therefore made a conditional 
recommendation against the routine use of remdesivir in preg-
nant and breastfeeding women outside of a trial setting (Table 3).
Hydroxychloroquine for treatment or for 
post-exposure prophylaxis
There are currently 11 trials (over 6300 patients) comparing hy-
droxychloroquine with standard care in the treatment of patients 
with COVID-19.56–66 In all trials, pregnant women were either 
excluded or their eligibility was not specified. Meta-analyses indi-
cate that hydroxychloroquine is potentially harmful and no more 
effective than standard care, leading to a strong recommenda-
tion against its use for COVID-19 treatment (Table 3). Separately, 
hydroxychloroquine for post-exposure prophylaxis has been 
evaluated in two trials (3135 participants), both of which excluded 
pregnant and breastfeeding women; however, there is currently 
insufficient evidence to assess benefits.67,68 The Taskforce recom-
mends that hydroxychloroquine for post-exposure prophylaxis 
should not be used outside of randomised trials with appropriate 
ethical approval, emphasising that further trials (including in preg-
nant and breastfeeding women) are needed.
Other disease-modifying treatments
The Taskforce has issued a further 19 recommendations on a 
wide range of disease-modifying treatments (Table 3), including: 
TABLE 3 Recommendations on use of disease-modifying treatments for pregnant or postpartum women with COVID-19†
Dexamethasone as 
treatment for COVID-19
1. Use dexamethasone 6 mg daily intravenously or orally for up to ten days in pregnant or breastfeeding women 
with COVID-19 who are receiving oxygen (including mechanically ventilated patients) (strong recommendation, 
low certainty evidence).
2. Do not routinely use dexamethasone to treat COVID-19 in pregnant or breastfeeding women who do not 
require oxygen (strong recommendation, low certainty evidence).
• Antenatal corticosteroids should still be used for fetal lung maturation in pregnant women at risk of pre-
term birth who also have COVID-19. Dexamethasone should still be used for other evidence-based indica-
tions in pregnant and breastfeeding women who have COVID-19.
Remdesivir as treatment 
for COVID-19
Use of remdesivir for pregnant or breastfeeding women with COVID-19 outside of a trial setting should not be 
considered routinely (conditional recommendation, very low certainty evidence).
• As pregnant and breastfeeding women are often excluded from clinical trials, use of remdesivir in this popula-
tion would be outside a clinical trial setting. Pregnant and breastfeeding women receiving remdesivir should 
nonetheless be enrolled in national COVID-19 registries. Currently, there is no direct evidence of the effects of 
remdesivir in pregnant and breastfeeding women. Information about the patients and the intervention (dos-
ages, duration) in the trials used for this recommendation can be found in the Practical info tab.




Do not use hydroxychloroquine for the treatment of COVID-19 (strong recommendation, moderate certainty 
evidence).
• This recommendation applies to adults, children and adolescents, pregnant and breastfeeding women, older 
people living with frailty and those receiving palliative care.
• Use of hydroxychloroquine may still be considered in the context of randomised trials with appropriate ethical 




For people exposed to individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, 
do not use hydroxychloroquine for post-exposure prophylaxis outside of randomised trials with appropriate 
ethical approval (strong recommendation, low certainty evidence).
Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding 
women, older people living with frailty and those receiving palliative care. Until further evidence is available, do 




For people with COVID-19, do not use the other disease-modifying treatments‡ outside of randomised trials with 
appropriate ethical approval (strong recommendation, very low certainty evidence).
• Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding 
women, older people living with frailty and those receiving palliative care. Until further evidence is available, 
do not use in these populations unless they are eligible to be enrolled in trials.
†Recommendations were current at the time of writing. Please visit The National COVID-19 Clinical Evidence Taskforce (https://covid 19evi dence.
net.au/) for the latest updates to the recommendations.
‡The treatments include: aprepitant, baloxavir marboxil, calcifediol, chloroquine, colchicine, convalescent plasma, darunavir-cobicistat, favipiravir, 
human mesenchymal stem cells, immunoglobulin plus methylprednisolone, interferon β-1a, interferon β-1b, interferon gamma, lopinavir-ritona-
vir, ruxolitinib, sofosbuvir-daclatasvir, telmisartan and umifenovir.
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aprepitant, azithromycin, baloxavir marboxil, calcifediol, chlo-
roquine, colchicine, convalescent plasma, darunavir-cobicistat, 
favipiravir, human mesenchymal stem cells, immunoglobulin plus 
methylprednisolone, interferon β-1a, interferon β-1b, interferon 
gamma, lopinavir-ritonavir, ruxolitinib, sofosbuvir-daclatasvir, tel-
misartan and umifenovir. These treatments have typically been 
evaluated in one or two trials with a small number of non-preg-
nant participants, resulting in low or very low certainty evidence 
from which no conclusions can be drawn. For some of these treat-
ments (such as baloxavir marboxil or favipiravir), no pregnancy 
safety data are available, whereas others (such as azithromycin 
or lopinavir-ritonavir) have a well-described safety profile.55 The 
Taskforce therefore recommends that these treatments should 
not be used outside of randomised trials, with emphasis that trials 
enrolling pregnant and breastfeeding women are needed.
Venous thromboembolism (VTE) prophylaxis
While COVID-19 infection appears to increase the risk of VTE, 
there is currently no direct evidence on the exact duration of this 
increased risk, or which prophylactic anticoagulant regimen is op-
timal.69 The consensus recommendations (Table 4) were formu-
lated based on a review of available international guidelines69,70 
and consultation with expert haematologists. Recognising that 
TABLE 4 Venous thromboembolism (VTE) prophylaxis in pregnant and postpartum women†
Pregnant women in general are at an increased risk of venous thromboembolism (VTE). Hospitalised pregnant women with an acute infective 
illness (such as COVID-19) are at even greater risk of VTE. However, the exact duration of increased risk of VTE in association with COVID-19 
infection is not yet established. All pregnant and postpartum women should undergo a documented assessment of risk factors for VTE on 
admission to hospital, if COVID-19 is diagnosed, if COVID-19 severity changes, and postpartum. The use of pharmacological prophylaxis in 
women should be accompanied by other measures to prevent VTE, such as anti-embolism stockings and sequential compression devices.
For pregnant or postpartum women who are admitted to hospital (for any indication) and who have COVID-19, use prophylactic doses of 
anticoagulants, preferably low-molecular weight heparin (LMWH: eg, enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless 
there is a contraindication, such as risk for major bleeding or imminent birth.
Prophylactic anticoagulants should be continued for at least 14 days after discharge or until COVID-19-related morbidity (including 
immobility, dehydration and/or shortness of breath) has resolved (consensus recommendation).
• Dosing of LMWH is dependent on pre-pregnancy body weight and current renal function.
• For women with early pregnancy body weight outside of 50-90 kg, consider adjusted LMWH dosing.
• There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.
For pregnant women with severe or critical COVID-19, or where there are additional risk factors for VTE, consider using increased 
prophylactic dosing of anticoagulants, preferably LMWH (eg, enoxaparin 40 mg twice daily or dalteparin 5000 IU twice daily) unless there is a 
contraindication, such as risk for major bleeding or platelet count < 30 × 109/L. Prophylactic anticoagulants should be continued for at least 
four weeks after discharge or until COVID-19-related morbidity (including immobility, dehydration and/or shortness of breath) has resolved 
(consensus recommendation).
• Dosing is dependent on pre-pregnancy body weight and current renal function. For women with early pregnancy body weight outside of 
50-90 kg, consider adjusted LMWH dosing.
• There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.
• Clinicians should refer to their local or jurisdictional guidance on additional VTE risk factors.
• In some situations, continuation of LMWH throughout the rest of pregnancy and postpartum may be required. Involvement of special-
ist obstetricians, obstetric medicine physicians, haematologists or other physicians with expertise in VTE in pregnant women would 
be warranted.
For pregnant or postpartum women who are self-isolating at home with mild COVID-19 and where additional risk factors for VTE are present, 
consider using prophylactic doses of anticoagulants, preferably LMWH (eg, enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) 
unless there is a contraindication, such as risk for major bleeding or imminent birth. Prophylactic anticoagulants should be continued 
for at least 14 days or until COVID-19-related morbidity (including immobility, dehydration and/or shortness of breath) has resolved. For 
pregnant or postpartum women who are self-isolating at home with mild COVID-19 and who have no additional risk factors for VTE, routine 
pharmacological prophylaxis is not recommended (consensus recommendation)
• Dosing of LMWH is dependent on pre-pregnancy body weight and current renal function. For women with early pregnancy body weight 
outside of 50–90 kg, consider adjusted LMWH dosing.
• There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.
• Clinicians should refer to their local or jurisdictional guidance on additional VTE risk factors.
For postpartum women who have had COVID-19 during pregnancy, consider using at least 14 days of prophylactic dosing of anticoagulants, 
preferably LMWH (eg, enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless there is a contraindication, such as risk for 
major bleeding. Increased duration of six weeks should be considered if severe or critical COVID-19 and/or additional risk factors for VTE are 
present (consensus recommendation)
• Dosing of LMWH is dependent on pre-pregnancy body weight and current renal function. For women with early pregnancy body weight 
outside of 50-90 kg, consider adjusted LMWH dosing.
• There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.
• Clinicians should refer to their local or jurisdictional guidance on additional VTE risk factors.
†Recommendations were current at the time of writing. Please visit The National COVID-19 Clinical Evidence Taskforce (https://covid 19evi dence.
net.au/) for the latest updates to the recommendations.
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pregnancy and the postpartum period are inherently hyperco-
agulable states, the statement emphasises that all pregnant and 
postpartum women should be assessed for additional risk factors 
for VTE on admission to hospital, when COVID-19 is diagnosed, if 
COVID-19 severity changes, and postpartum.
Prone positioning and extracorporeal 
membrane oxygenation (ECMO)
Internationally, there are few (and somewhat conflicting) guide-
lines on the use of prone positioning or ECMO in pregnant and 
postpartum women with COVID-19.4,71–74 There is currently no 
primary evidence on their benefits and harms in these women, 
although it is known to be effective in some groups of adult 
patients with critical disease.75,76 Recent reports describe their 
use in small numbers of pregnant women with critical COVID-
19 disease.77–80 The Taskforce recommends that prone position-
ing be considered in women receiving any form of supplemental 
oxygen therapy or mechanically ventilated women, although 
care should be taken to support the gravid uterus and reduce 
aorta-caval compression (Table  5). Referral to an ECMO centre 
for veno-venous ECMO can be considered for mechanically venti-
lated pregnant women, although this decision needs to consider 
gestational age, fetal viability, fetal well-being, and the risks and 
benefits to woman and baby. The Taskforce has issued separate 
recommendations on other respiratory support interventions 
that apply to adults (whether pregnant or non-pregnant), in-
cluding the use of high-flow nasal oxygen therapy, noninvasive 
ventilation, respiratory management of the deteriorating patient, 
videolaryngoscopy, neuromuscular blockers, positive end-expir-
atory pressure and recruitment manoeuvres. These can be found 
on the Taskforce website.21
DISCUSSION
The treatment of COVID-19 is a rapidly expanding area of re-
search, with an unprecedented global effort underway. However, 
with more than 53 000 COVID-19 articles in PubMed, as well as 
2100 systematic review protocols and 1600 trial protocols regis-
tered online in less than eight months, it is increasingly difficult for 
clinicians to remain up-to-date on important developments.15,21,81 
There is also a growing recognition that a portion of the COVID-19 
literature is of poor quality, further complicating its interpretation 
and application in clinical care.82 The living guideline approach 
ensures that new, important evidence is rapidly translated into 
clinical recommendations, without compromising quality or rig-
our of guideline development. While living guidelines methods 
have been successfully applied to Australian guidelines on stroke 
and diabetes,18,83 the approach of weekly updating used by this 
Taskforce is the most frequent of which we are aware. While 
resource-intensive, the collaborative effort of over 220 clinical 
experts nationwide, as well as support from commonwealth, 
state and territory governments and other funders, has shown 
this model to be highly feasible in the context of a global public 
health emergency.
TABLE 5 Respiratory support for pregnant and postpartum women with severe or critical COVID-19†
Prone 
positioning
1. For mechanically ventilated pregnant women with COVID-19 and hypoxaemia despite optimising ventilation, consider 
prone positioning for more than 12 h a day (consensus recommendation).
2. For pregnant and postpartum women with COVID-19 and respiratory symptoms who are receiving any form of sup-
plemental oxygen therapy and have not yet been intubated, consider prone positioning. When positioning a pregnant 
woman in prone, care should be taken to support the gravid uterus to reduce aorta-caval compression. Women 
who are deteriorating should be considered for early endotracheal intubation and invasive mechanical ventilation. 
Birth of the baby should be considered when it may enhance maternal resuscitation or be beneficial to the fetus 
(consensus recommendation).
• Current reports suggest prone ventilation in adult patients is effective in improving hypoxia associated with COVID-
19. This should be done in the context of a hospital guideline that includes suitable personal protective equipment 
for staff, and that minimises the risk of adverse events, e.g. accidental extubation.
• Proning of a pregnant woman should avoid abdominal compression and ensure a woman's hips and chest are sup-
ported. In the absence of specialised equipment, proning can be performed using pillows and blankets.





Consider referral to an ECMO centre for venovenous ECMO in mechanically ventilated pregnant women with COVID-19 
and refractory respiratory failure (despite optimising ventilation, including proning). Delivery of the baby prior to ECMO to 
enhance maternal resuscitation should be considered on a case-by-case basis (consensus recommendation).
• Due to the resource-intensive nature of ECMO and the need for experienced centres, healthcare workers and infra-
structure, ECMO should only be considered in selected pregnant women with COVID-19 and severe ARDS.
• The decision on whether to use ECMO should be taken in consultation with the woman's family, as well as obstetric and 
intensive care specialists. Key considerations include gestational age, fetal viability, fetal well-being and the risks and 
benefits to mother and baby.
• Early referral to an ECMO centre is preferred.
• As pregnant and postpartum women may have haemostatic alterations, anticoagulation regimens may need to be 
modified appropriately.
†Recommendations were current at the time of writing. Please visit The National COVID-19 Clinical Evidence Taskforce (https://covid 19evi dence.
net.au/) for the latest updates to the recommendations.
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A key finding from these recommendations is the lack of di-
rect evidence specific to pregnant and breastfeeding women 
with COVID-19. Historically, women (and particularly pregnant 
and breastfeeding women) have been excluded from adult clin-
ical trials, despite repeated calls from professional associations, 
regulatory agencies and researchers for their inclusion.84–86 This 
trend has continued in the era of COVID-19, with pregnant and 
breastfeeding women excluded from large multi-centre trials 
of COVID-19 therapeutics.87 Pastick et al. reported that in 1282 
ongoing COVID-19 therapeutic clinical trials enrolling people of 
reproductive age, only 48 explicitly confirmed that pregnant and 
breastfeeding women could be enrolled.88 Exclusion of preg-
nant women from COVID-19 trials creates uncertainty regarding 
safety and effectiveness of promising management strategies, 
and ultimately leads to reduced access to important treatments. 
Consequently, the Taskforce recommendations have considered 
whether available evidence from trials of non-pregnant adults can 
be generalised to pregnant and breastfeeding women.
These recommendations are intended to be used in conjunc-
tion with existing principles and guidelines on routine maternity 
care. However, living recommendations can require more dy-
namic approaches to implementation. Clinicians and other stake-
holders need to be continually updated regarding new or revised 
recommendations, and clinical tools (such as flowcharts and algo-
rithms) need to be regularly revised to align with updated recom-
mendations. Since their launch, the Taskforce website has been 
visited over 180  000 times. We encourage hospital and clinical 
networks to sign up to the free weekly email updates, and update 
their jurisdictional guidance or local clinical protocols as neces-
sary. While the scope of the living guidelines has thus far focused 
on clinical care of people with COVID-19, on 9 September 2020 
the Commonwealth Government announced a new partnership 
between the Taskforce and the Infection Control Expert Group 
(ICEG) to apply the living guidelines model to selected infection 
prevention and control issues in Australian healthcare settings.89
CONCLUSION
Living guidelines are an innovative model than can accelerate the 
translation of new evidence into clinical practice. The National 
COVID-19 Clinical Evidence Taskforce has published 18 pregnancy 
and perinatal living recommendations, which will be updated as 
necessary in response to new, important evidence. We encour-
age clinicians in Australia’s maternity services to freely subscribe 
to Taskforce updates (covid19evidence.net.au) to ensure they re-
main abreast of guideline updates.
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